Susceptibility of Clinical Isolates to Expanded-Spectrum β-Lactams Alone and in the Presence of β-Lactamase Inhibitors

Chemotherapy

Volumn 42, Issue 5, 1996, Pages 334-342

  Qadri, S M Hussain ^a   Veno, Yoshio ^a   Cunha, Burke A ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Antibacterial agents; BRL 42715; Clavulanic acid; In vitro activity; Penem; Tazobactam; Lactamase inhibitors

Indexed keywords

6 (1 METHYL 1,2,3 TRIAZOL 4 YLMETHYLENE)PENEM 3 CARBOXYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CLAVULANIC ACID; ERYTHROMYCIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TETRACYCLINE; TICARCILLIN; TIMENTIN;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; DRUG POTENTIATION; ENTEROBACTER; ENTEROBACTERIACEAE; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; SERRATIA; STAPHYLOCOCCUS AUREUS;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CLAVULANIC ACID; CLAVULANIC ACIDS; DRUG SYNERGISM; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; LACTAMS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; STAPHYLOCOCCUS AUREUS; TICARCILLIN;

EID: 0029845363     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000239464     Document Type: Article

References (28)

1. Bell SM, Plowman D: Mechanisms of ampicillin resistance in Haemophilus influenzae from respiratory tract. Lancet 1980;i:279-280.
2. Rammelkamp CH, Moxton T: Resistance of Staphylococcus aureus to the action of penicillin. Proc Soc Biol 1942,51:386.
3. Richmond Mh: ß-Lactamase. Int J Clin Pharmacol Biopharm 1979;17: 135-136.
4. Aronof TSC, Jacobs MR, Johenning HS, Jamabe S: Comparative activities of the (3-lactamase inhibitors YTR 830, sodium clavulanatc and sulbactam combined with amoxycillin or ampicillin. Antimicrob Agents Chemother 1984;26:380-382.
5. Coleman K, Griffin DRJ, Page JWJ, Upshon PA: In-vitro evaluation of BRL 42715, a novel β-lactamase inhibitor. Antimicrob Agents Chemother 1989;33:1580-1587.
6. Goldstein FW, Kitzis MP, Malhurst C: Clinical evaluation of the formulation clavulanic acid plus amoxycillin in the treatment of urinary tract infections due to P-lactamase producing bacteria. Curr Chemother Infect Dis 1980;1:354-351.
7. Hunter PA, Coleman K, Fisher J, Taylor D: In-vitro synergistic properties of clavulanic acid with ampicillin, amoxycillin and ticarcillin. J Antimicrob Chemother 1980;6: 455-470.
8. Qadri SMH. Ueno Y, Burdette JM, Kroschinsky RM, Almodovar E: Evaluation of BRL 42715, a p-lacta-mase-inhibiting penem. Chemotherapy 1991;37:398-404.
9. Moosdcen F, Williams JD, Yamabe S: Antibacterial characteristics of YTR 830. a sulfonc β-lactamasc inhibitor. compared with those of cla-vulanic acid and sulbactam. Antimi-crob Agents Chcmother 1988:32: 925-928.
10. Clarke AM, Zcmcov SJV: Clavu-lanic acid in combination with ticar-cillin; An in vitro comparison with other α-lactams. J Antimicrob Chcmother 1984;13:121-128.
11. Labia R, Morrand A, Peduzzin J: Timentin and p-lactamases. J Antimicrob Chcmother 1986; 177 (suppl C): 17-26.
12. Akova M, Yang Y, Livermore DM: Interactions of tazobactam and cla-vulanate with inducibly and consti-tutively expressed class 1 p-lacta-mascs. J Antimicrob Chemothcr 1990;25:199-208.
13. Livermore DM, Scctulsing P: Susceptibility of Escherichia coli with TEM-1 p-lactamasc to combinations of BRL 42715, tazobactam or clavulanate with piperacillin or amoxycillin. J Antimicrob Che-mother 1991;27:761-767.
14. Zhou XY, Kitziz MD, Acar JF, Gut-mann L: Activity of the p-lactamase inhibitor BRL 42715 against cepha-losporinascs produced by Entero-bacteriaceac. J Antimicrob Che-mother 1993;31:473-480.
15. Murray PR, Baron MJ, Pfaller MA, TenoverFC, Yolken RH: Manual of Clinical Microbiology, ed 6. Washington. American Society for Microbiology, 1995.
16. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests of Bacteria that Grow Aerobically. Approved Standard M7-A2. Villanova, NCCLS. 1990
17. Jones RN, Barry AL: Studies to optimize the in-vitro testing of piperacillin combined with tazobactam (YTR 83). Diagn Microbiol Infect Dis 1989:12:495-510.
18. Chen HY, Binfiglio G, Allen M. Piper D, EdwardsonT: Multiccntre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles. J Antimicrob Chemother 1993:32:247-266.
19. Bry son HM, Brogden RN: Pipcracil-lin/tazobactam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-535.
20. Catherall EJ, Mizen L: Protection of amoxycillin and ticarcillin with cla-vulanic acid from inactivation by P-lactamases in experimental localized infections. Drugs Exp Clin Res 1984;10:697-702.
21. Barry AL, Ayers LW, Gavan TL, Gcrlach EH. Jone RN: In vitro activity of ticarcillin plus clavulanic acid against bacteria isolated in three centers. Eur J Clin Microbiol 1984;3:203-206.
22. Kasai T, NishinoT, KazunoY, Tan-ino T: The antibacterial activity of ticarcillin/clavulanic acid (BRL 28500) against ticarcillin-resistant bacteria. J Antibiot 1986:39:1450-1460.
23. Sirot D. Canal C, Hcnqucll C, Labia R, Sirto J, Cluzcl R: Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to p-lac-tamase inhibitors. J Antimicrob Chemothcr 1994;33:1117-1126.
24. Farrar WE: Antibiotic resistance in developing countries. J Infect Dis 1985;152:1103-1106.
25. Murray BE, Alvarado T, Kim KH: Increasing resistance to trimetho-prim-sulfame-thoxazolc among isolates of Escherichia coli in developing countries. J Infect Dis 1985:152: 1107-1113.
26. Qadri SMH, Kroschinsky RM, Cun-ha BA: Similarities and differences in the antimicrobial resistance of clinical isolates in Saudi Arabia and the United States. Curr Ther Res 1990;47:130-135.
27. Shibl AM: Incidence of p-lactamase production among outpatient clinical isolates in Middle Eastern countries and their antibiotic susceptibilities. Chemotherapy 1992:38:324-329.
28. Qadri SMH, Huber TW, Lee GC, Al-Hajjar S: Antimicrobial resistance of bacterial pathogens at two tertiary care centers, in Riyadh and Texas. Tex Med 1994;90:59-62.